KRN 5500

Drug Profile

KRN 5500

Alternative Names: KRN5500; NSC-650426; SPK-241

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Brewery; Massachusetts General Hospital
  • Developer Midatech Pharma US
  • Class Cytostatic antibiotics; Non-opioid analgesics; Purine nucleosides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuropathic pain
  • No development reported Multiple myeloma
  • Discontinued Cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV)
  • 02 Nov 2015 KRN 5500 is still available for licensing in USA
  • 02 Nov 2015 DARA BioSciences receives extension of patent protection for KRN 5500 through a issued formulation patent in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top